One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The source introductory threshold is rendered =60; the source table is preserved separately. This is not a newly verified label transcription.
Label and institutional sources include daily dosing and post-dialysis-only schedules. Their indication, dialysis frequency, infusion, and exposure assumptions differ.
What to reconcile: Select one complete locally approved regimen; do not add a daily dose on top of a post-HD-only schedule.
Open this note and its source referencesThe MAXIPIME mirror uses daily maintenance; UCSF describes a post-HD strategy and a separate unstable-schedule alternative.
What to reconcile: Resolve indication, dialysis timing and local specialist protocol before selecting a regimen; do not average or mix schedules.
Open this note and its source referencesThese are separately selected institutional strategies; do not merge short-infusion, extended-infusion or dialysis instructions.
| CrCl, mL/min | Source-specific dose / instruction |
|---|---|
| >60 | 2 g every 12 hours |
| 30-60 | 2 g every 24 hours |
| 10-29 | 1 g every 24 hours |
| <10 | 500 mg every 24 hours |
| CrCl, mL/min | Source-specific dose / instruction |
|---|---|
| >60 | 2 g every 8 hours |
| 30-60 | 2 g every 12 hours |
| 10-29 | 2 g every 24 hours |
| <10 | 1 g every 24 hours |
| CrCl, mL/min | Source-specific dose / instruction |
|---|---|
| >60 | 2 g over 4 hours every 8 hours |
| 30-60 | 2 g over 4 hours every 12 hours |
| <30 | Use short infusion, not this extended-infusion pathway |
2 g loading dose over 30 minutes; start maintenance 4 hours after loading. Extended-infusion evidence in meningitis is limited.
| Dialysis setting / indication | Source-specific schedule |
|---|---|
| IHD | 2 g initially and following dialysis |
| IHD with unstable schedule - alternative | 1 g initially, then each evening |
| CVVHD | 1 g every 8 hours |
All doses below are IV. For CrCl >60 / 30-60 / 10-29 / <10 mL/min, respectively:
Intermittent HD: 2 g initially and following dialysis. When the dialysis schedule is unstable, the alternative is 1 g initially, then every evening. CVVHD: 1 g every 8 hours.
A separate specialist-selected extended-infusion regimen uses a 2 g loading dose over 30 minutes, then 2 g over 4 hours every 8 hours when CrCl >60 or every 12 hours at 30-60. Start maintenance 4 hours after loading; use short infusion below 30. Meningitis extended-infusion evidence is limited.
RDM30-001-cefepime-1 · Source locator: UCSF - cefepime: short infusion and dialysis; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=cefepime&s1=RDM30-001-cefepime&h1=369628baa12e9837dfe2ac40da7c696d434779801880c50f33b27cae6edfd91d